Corrigendum: Expression of the CTLA-4 ligand CD86 on plasmacytoid dendritic cells (pDC) predicts risk of disease recurrence after treatment discontinuation in CML (Leukemia (2017) 31 (829-836) DOI: 10.1038/leu.2017.9);Expression of the CTLA-4 ligand CD86 on plasmacytoid dendritic cells (pDC) predicts risk of disease recurrence after treatment discontinuation in CML

Leukemia

Volumn 31, Issue 4, 2017, Pages 829-836

  Schutz C ^a   Inselmann, S ^a   Sausslele, S ^b   Dietz, C T ^b   Muller M C ^b   Eigendorff, E ^c   Brendel, C A ^a   Metzelder, S K ^a   Brummendorf T H ^d   Waller, C ^e   Dengler, J ^f   Goebeler, M E ^g   Herbst, R ^h   Freunek, G ⁱ   Hanzel, S ^j   Illmer, T ^k   Wang, Y ^a   Lange, T ^l   Finkernagel, F ^m   Hehlmann, R ^b   Huber, M ^m   Neubauer, A ^a   Hochhaus, A ^c   Guilhot, J ⁿ   Xavier Mahon, F ^o   Pfirrmann, M ^p   Burchert, A ^a   more..

^a UNIVERSITY HOSPITAL MARBURG   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

^c JENA UNIVERSITY HOSPITAL   (Germany)

^d UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

^e UNIVERSITY OF FREIBURG   (Germany)

^f Onkologische Praxis Heilbronn   (Germany)

^g UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

^h KLINIKUM CHEMNITZ   (Germany)

ⁱ Strahlentherapie   (Germany)

^j Klinikum Kempten Oberallgau   (Germany)

^k Jacobasch Wolf   (Germany)

^l Department for Hematology Oncology   (Germany)

^m PHILIPPS UNIVERSITY MARBURG   (Germany)

ⁿ Clinical Center   (France)

^o BORDEAUX UNIVERSITY HOSPITAL   (France)

^p UNIVERSITY OF MUNICH   (Germany)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; BCR ABL PROTEIN; CD86 ANTIGEN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DASATINIB; IMATINIB; NILOTINIB; PROTEIN TYROSINE KINASE INHIBITOR; BIOLOGICAL MARKER; PROTEIN KINASE INHIBITOR;

ACCURACY; ADULT; AGED; ARTICLE; CANCER PROGNOSIS; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; FEMALE; FLOW CYTOMETRY; FLUORESCENCE ACTIVATED CELL SORTING; HUMAN; IMMUNOLOGICAL TOLERANCE; LEUKEMIA REMISSION; MAJOR CLINICAL STUDY; MALE; PHASE 2 CLINICAL TRIAL; PLASMACYTOID DENDRITIC CELL; PREDICTION AND FORECASTING; PROTEIN EXPRESSION; RECURRENT DISEASE; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; TRANSLATIONAL RESEARCH; CELL COUNT; DENDRITIC CELL; GENE EXPRESSION; GENETICS; IMMUNOLOGY; IMMUNOPHENOTYPING; KAPLAN MEIER METHOD; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; METABOLISM; MIDDLE AGED; MORTALITY; PROGNOSIS; REMISSION; T LYMPHOCYTE SUBPOPULATION; TREATMENT OUTCOME; YOUNG ADULT;

ADULT; AGED; ANTIGENS, CD86; BIOMARKERS; CELL COUNT; CTLA-4 ANTIGEN; DENDRITIC CELLS; FEMALE; GENE EXPRESSION; HUMANS; IMMUNOPHENOTYPING; KAPLAN-MEIER ESTIMATE; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MALE; MIDDLE AGED; PROGNOSIS; PROTEIN KINASE INHIBITORS; RECURRENCE; REMISSION INDUCTION; T-LYMPHOCYTE SUBSETS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 85010894676     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2017.348     Document Type: Erratum

References (56)

1. Hehlmann R, Müller MC, Lauseker M, Hanfstein B, Fabarius A, Schreiber A et al. Deep molecular response is reached by the majority of patients treated with imatinib, predicts survival, and is achieved more quickly by optimized high-dose imatinib: results from the randomized CML-Study IV. J Clin Oncol 2013; 32: 415-423
2. Jabbour E, Kantarjian HM, Saglio G, Steegmann JL, Shah NP, Boqué C et al. Early response with dasatinib or imatinib in chronic myeloid leukemia: 3-year follow-up from a randomized phase 3 trial (DASISION). Blood 2014; 123: 494-500
3. Larson RA, Hochhaus A, Hughes TP, Clark RE, Etienne G, Kim DW et al. Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-up. Leukemia 2012; 26: 2197-2203
4. Graham SM, Jørgensen HG, Allan E, Pearson C, Alcorn MJ, Richmond L et al. Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro. Blood 2002; 99: 319-325
5. O'Hare T, Zabriskie MS, Eiring AM, Deininger MW. Pushing the limits of targeted therapy in chronic myeloid leukaemia. Nat Rev Cancer 2012; 12: 513-526
6. Branford S, Yeung DT, Ross DM, Prime JA, Field CR, Altamura HK et al. Early molecular response and female sex strongly predict stable undetectable BCR-ABL1, the criteria for imatinib discontinuation in patients with CML. Blood 2013; 121: 3818-3824
7. Hughes TP, Kaeda J, Branford S, Rudzki Z, Hochhaus A, Hensley ML et al. Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. N Engl J Med 2003; 349: 1423-1432
8. Cortes J, O'Brien S, Kantarjian H. Discontinuation of imatinib therapy after achieving a molecular response. Blood 2004; 104: 2204-2205
9. Rousselot P, Huguet F, Réa D, Legros L, Cayuela JM, Maarek O et al. Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years. Blood 2007; 109: 58-60
10. Mauro MJ, Druker BJ, Maziarz RT. Divergent clinical outcome in two CML patients who discontinued imatinib therapy after achieving a molecular remission. Leukemia Res 2004; 28(Suppl 1): S71-S73
11. Merante S, Orlandi E, Bernasconi P, Calatroni S, Boni M, Lazzarino M. Outcome of four patients with chronic myeloid leukemia after imatinib mesylate discontinuation. Haematologica 2005; 90: 979-981
12. Mahon F-X, Réa D, Guilhot J, Guilhot F, Huguet F, Nicolini F et al. Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial. Lancet Oncol 2010; 11: 1029-1035
13. Rousselot P, Charbonnier A, Cony-Makhoul P, Agape P, Nicolini FE, Varet B et al. Loss of major molecular response as a trigger for restarting tyrosine kinase inhibitor therapy in patients with chronic-phase chronic myelogenous leukemia who have stopped imatinib after durable undetectable disease. J Clin Oncol 2013; 32: 424-430
14. Ross DM, Branford S, Seymour JF, Schwarer AP, Arthur C, Yeung DT et al. Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study. Blood 2013; 122: 515-522
15. Cross NCP, White HE, Müller MC, Saglio G, Hochhaus A. Standardized definitions of molecular response in chronic myeloid leukemia. Leukemia 2012; 26: 2172-2175
16. Müller MC, Cross NCP, Erben P, Schenk T, Hanfstein B, Ernst T et al. Harmonization of molecular monitoring of CML therapy in Europe. Leukemia 2009; 23: 1957-1963
17. Cross NCP, White HE, Colomer D, Ehrencrona H, Foroni L, Gottardi E et al. Laboratory recommendations for scoring deep molecular responses following treatment for chronic myeloid leukemia. Leukemia 2015; 29: 999-1003
18. Ross DM, Hughes TP. How I determine if and when to recommend stopping tyrosine kinase inhibitor treatment for chronic myeloid leukaemia. Br J Haematol 2014; 166: 3-11
19. Ilander M, Hekim C, Mustjoki S. Immunology and immunotherapy of chronic myeloid leukemia. Curr Hematol Malig Rep 2014; 9: 17-23
20. Mahon FX, Delbrel X, Cony-Makhoul P, Fabères C, Boiron JM, Barthe C et al. Follow-up of complete cytogenetic remission in patients with chronic myeloid leukemia after cessation of interferon alfa. J Clin Oncol 2002; 20: 214-220
21. Bonifazi F, Vivo A, Rosti G, Guilhot F, Guilhot J, Trabacchi E et al. Chronic myeloid leukemia and interferon-alpha: a study of complete cytogenetic responders. Blood 2001; 98: 3074-3081
22. Hochhaus A, Reiter A, Saußele S, Reichert A, Emig M, Kaeda J et al. Molecular heterogeneity in complete cytogenetic responders after interferon-alpha therapy for chronic myelogenous leukemia: low levels of minimal residual disease are associated with continuing remission. German CML Study Group and the UK MRC CML Study Group. Blood 2000; 95: 62-66
23. Talpaz M, Estrov Z, Kantarjian H, Ku S, Foteh A, Kurzrock R. Persistence of dormant leukemic progenitors during interferon-induced remission in chronic myelogenous leukemia. Analysis by polymerase chain reaction of individual colonies. J Clin Invest 1994; 94: 1383-1389
24. Kantarjian HM, O'Brien S, Cortes JE, Shan J, Giles FJ, Rios MB et al. Complete cytogenetic and molecular responses to interferon-alpha-based therapy for chronic myelogenous leukemia are associated with excellent long-term prognosis. Cancer 2003; 97: 1033-1041
25. Burchert A, Saußele S, Eigendorff E, Müller MC, Sohlbach K, Inselmann S et al. Interferon alpha 2 (IFN) maintenance therapy may enable high rates of treatment discontinuation in chronic myeloid leukemia (CML). Leukemia 2015; 29: 1331-1335
26. Talpaz M, Kantarjian HM, McCredie KB, Keating MJ, Trujillo J, Gutterman J. Clinical investigation of human alpha interferon in chronic myelogenous leukemia. Blood 1987; 69: 1280-1288
27. Talpaz M, Hehlmann R, Quintás-Cardama A, Mercer J, Cortes J. Re-emergence of interferon-α in the treatment of chronic myeloid leukemia. Leukemia 2013; 27: 803-812
28. Crouse J, Kalinke U, Oxenius A. Regulation of antiviral T cell responses by type I interferons. Nat Rev Immunol 2015; 15: 231-242
29. Molldrem JJ, Lee PP, Wang C, Felio K, Kantarjian HM, Champlin RE et al. Evidence that specific T lymphocytes may participate in the elimination of chronic myelogenous leukemia. Nat Med 2000; 6: 1018-1023
30. Burchert A, Wölfl S, Schmidt M, Brendel C, Denecke B, Cai D et al. Interferon-alpha, but not the ABL-kinase inhibitor imatinib (STI571), induces expression of myeloblastin and a specific T-cell response in chronic myeloid leukemia. Blood 2003; 101: 259-264
31. Burchert A, Müller MC, Kostrewa P, Erben P, Bostel T, Liebler S et al. Sustained molecular response with interferon alfa maintenance after induction therapy with imatinib plus interferon alfa in patients with chronic myeloid leukemia. J Clin Oncol 2010; 28: 1429-1435
32. Chen L. Co-inhibitory molecules of the B7-CD28 family in the control of T-cell immunity. Nat Rev Immunol 2004; 4: 336-347
33. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 2012; 12: 252-264
34. Francisco LM, Sage PT, Sharpe AH. The PD-1 pathway in tolerance and autoimmunity. Immunol Rev 2010; 236: 219-242
35. Asselin-Paturel C, Boonstra A, Dalod M, Durand I, Yessaad N, Dezutter-Dambuyant C et al. Mouse type I IFN-producing cells are immature APCs with plasmacytoid morphology. Nat Immunol 2001; 2: 1144-1150
36. Reizis B, Colonna M, Trinchieri G, Barrat F, Gilliet M. Plasmacytoid dendritic cells: one-trick ponies or workhorses of the immune system? Nat Rev Immunol 2011; 11: 558-565
37. Goubier A, Dubois B, Gheit H, Joubert G, Villard-Truc F, Asselin-Paturel C et al. Plasmacytoid dendritic cells mediate oral tolerance. Immunity 2008; 29: 464-475
38. Villadangos JA, Young L. Antigen-presentation properties of plasmacytoid dendritic cells. Immunity 2008; 29: 352-361
39. Gilliet M, Liu Y-J. Generation of human CD8 T regulatory cells by CD40 ligand-activated plasmacytoid dendritic cells. J Exp Med 2002; 195: 695-704
40. Therneau TM, Grambsch PM. Modeling Survival Data: Extending the Cox Model. Terry M. Therneau, (Springer. springer.com, 2000). Available at: http://www. springer.com/us/book/9780387987842 (Accessed 16 April 2016)
41. Altman DG, Lausen B, Sauerbrei W, Schumacher M. Dangers of using 'optimal' cutpoints in the evaluation of prognostic factors. J Natl Cancer Inst 1994; 86: 829-835
42. Hothorn T, Hornik K, Zeileis A. Unbiades Recursive Partitioning: A Conditional Interfernce Framework. statmath.wu-wien.ac.at. 2006. Available at: http://stat math.wu-wien.ac.at/ ~ zeileis/papers/Hothorn+Hornik+Zeileis-2006.pdf (Accessed 16 April 2016)
43. Davison AC, Hinkley DV. Bootstrap Methods and Their Application. statwww.epfl.ch. Available at: http://statwww.epfl.ch/davison/BMA/CUPsample.pdf (Accessed 16 April 2016)
44. Silverman BW. Density estimation for statistics and data analysis. ned.ipac.caltech.edu. Available at: https://ned.ipac.caltech.edu/level5/March02/Silverman/paper.pdf (Accessed 16 April 2016)
45. Altman DG, JM B. Diagnostic tests. 1: Sensitivity and specificity.-PubMed-NCBI. Available at: http://www.ncbi.nlm.nih.gov/pubmed/8019315
46. Diagnostic tests 2: Predictive values.-PubMed-NCBI. Available at: http://www. ncbi.nlm.nih.gov/pubmed/8038641
47. Mahon F-X, Richter J, Guilhot J, Müller MC, Dietz C, Kimmoo P et al. Interim Analysis of a Pan European Stop Tyrosine Kinase Inhibitor Trial in Chronic Myeloid Leukemia : The EURO-SKI study. Blood 2014; 124: 151
48. Moseman EA, Liang X, Dawson AJ, Panoskaltsis-Mortari A, Krieg AM, Liu Y-J et al. Human plasmacytoid dendritic cells activated by CpG oligodeoxynucleotides induce the generation of CD4+CD25+ regulatory T cells. J Immunol 2004; 173: 4433-4442
49. Sawant A, Hensel JA, Chanda D, Harris BA, Siegal GP, Maheshwari A et al. Depletion of plasmacytoid dendritic cells inhibits tumor growth and prevents bone metastasis of breast cancer cells. J Immunol 2012; 189: 4258-4265
50. Molldrem JJ, Lee PP, Kant S, Wieder E, Jiang W, Lu S et al. Chronic myelogenous leukemia shapes host immunity by selective deletion of high-avidity leukemiaspecific T cells. J Clin Invest 2003; 111: 639-647
51. Ochando JC, Homma C, Yang Y, Hidalgo A, Garin A, Tacke F et al. Alloantigen-presenting plasmacytoid dendritic cells mediate tolerance to vascularized grafts. Nat Immunol 2006; 7: 652-662
52. Perez VL, Van Parijs L, Biuckians A, Zheng XX, Strom TB, Abbas AK. Induction of peripheral T cell tolerance in vivo requires CTLA-4 engagement. Immunity 1997; 6: 411-417
53. Ueda H, Howson JMM, Esposito L, Heward J, Snook H, Chamberlain G et al. Association of the T-cell regulatory gene CTLA4 with susceptibility to autoimmune disease. Nature 2003; 423: 506-511
54. Salomon B, Lenschow DJ, Rhee L, Ashourian N, Singh B, Sharpe A et al. B7/CD28 costimulation is essential for the homeostasis of the CD4+CD25+ immunoregulatory T cells that control autoimmune diabetes. Immunity 2000; 12: 431-440
55. Ilander M, Olsson-Strömberg U, Schlums H, Guilhot J, Brück O, Lähteenmäki H et al. Increased proportion of mature NK cells is associated with successful imatinib discontinuation in chronic myeloid leukemia. Leukemia 2016; e-pub ahead of print 16 December 2016; doi:10.1038/leu.2016.360
56. Vasaturo A, Di Blasio S, Peeters DGA, Koning CCH, Vries JM, Figdor CG et al. Clinical implications of co-inhibitory molecule expression in the tumor microenvironment for DC vaccination: a game of stop and Go. Front Immunol 2013; 4: 417